April 18-22, 2015 | Philadelphia, PA | Annual AACR meeting








The prestigious American Association for Cancer Research (AACR) Annual Meeting is one of the highlights of the year for oncology researchers. The 2015 meeting is a five-day event opening April 18 that is expecting more than 17,000 participants from 60 countries. The accompanying exhibitions will feature some 350 organizations from around the world.


XenTech present two posters to the meeting. The first arises from its partnership with Miltenyi Biotec to develop sialyl-glycolipid SSEA4 to mark a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.

Predictive Biomarkers 2 – Tuesday Arp 21, 1:00PM – 5:00PM – Section 25 #4317.


XenTech will also post a report on its partnership with AstraZeneca to research use of the MET inhibitor AZD6094 (also called Savolitinib or HMPL-504) to induce regression in papillary renal cell carcinoma patient derived xenograft models.

 Human-in-Mouse Models of Cancer 1 – Monday Apr 20, 2015 8:00 AM – 12:00 PM – Section 17 #1477.


XenTech will be offering new partnership projects at AACR and Dr. Judde’s presence in Philadelphia provides unique opportunities for collaborators and potential partners to address scientific questions at high level and to acquire strategic insights.